Fraunhofer Institute for Translational Medicine and Pharmacology, Frankfurt am Main, Germany; Janssen Pharmaceutica NV, Pharmaceutical & Material Sciences, Beerse, Belgium.
Janssen Pharmaceutica NV, Pharmaceutical & Material Sciences, Beerse, Belgium.
J Pharm Sci. 2024 Sep;113(9):2940-2946. doi: 10.1016/j.xphs.2024.06.014. Epub 2024 Jun 20.
Supersaturation and precipitation within the gastrointestinal tract can influence oral absorption of active pharmaceutical ingredients (APIs). Supersaturation of weakly basic APIs upon transfer from the stomach into the small intestine may enhance their absorption, while salt forms of poorly soluble weak acids may generate supersaturated solutions in both stomach and intestine. Likewise, APIs with solubility-limited absorption may be developed as enabling formulations intended to produce supersaturated solutions of the API in the gut. Integrating the supersaturation/precipitation characteristics of the API into the biopharmaceutical risk classification enables comprehensive mapping of potential developability risks and guides formulation selection towards optimizing oral bioavailability (BA). The refined Developability Classification System (rDCS) provides an approach for this purpose. In this work, the rDCS strategy is revisited and a stratified approach integrating the in vitro supersaturation and precipitation behavior of APIs and their formulations is proposed.
在胃肠道内的过饱和和沉淀会影响活性药物成分(APIs)的口服吸收。弱碱性 API 从胃转移到小肠时的过饱和可能会增强其吸收,而溶解度差的弱酸的盐形式可能会在胃和肠道中产生过饱和溶液。同样,具有溶解度限制吸收的 APIs 可以被开发为使 API 在肠道中产生过饱和溶液的赋形剂配方。将 API 的过饱和/沉淀特性纳入生物制药风险分类中,可以全面映射潜在的可开发性风险,并指导制剂选择以优化口服生物利用度(BA)。为此,精制的可开发性分类系统(rDCS)提供了一种方法。在这项工作中,重新审视了 rDCS 策略,并提出了一种分层方法,该方法整合了 APIs 及其制剂的体外过饱和和沉淀行为。